Realcan Pharmaceutical Group Co., Ltd. (SHE:002589)
China · Delayed Price · Currency is CNY 3.270
-0.020 (-0.61%)
At close: Feb 13, 2026
SHE:002589 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 7,255 | 7,904 | 7,976 | 12,264 | 20,913 | 26,985 |
Other Revenue | 62.07 | 62.07 | 57.97 | 47.5 | 146.6 | 248.62 |
| 7,317 | 7,966 | 8,034 | 12,311 | 21,060 | 27,234 | |
Revenue Growth (YoY) | -8.38% | -0.85% | -34.74% | -41.54% | -22.67% | -22.76% |
Cost of Revenue | 6,612 | 7,096 | 7,212 | 10,683 | 17,315 | 22,374 |
Gross Profit | 704.42 | 870.74 | 822.06 | 1,628 | 3,745 | 4,860 |
Selling, General & Admin | 704.79 | 749.93 | 835.99 | 1,503 | 2,668 | 3,201 |
Research & Development | 13.07 | 10.03 | 14.62 | 22.68 | 11.56 | 8.91 |
Other Operating Expenses | 40.11 | 36.91 | 45.72 | 52.13 | 93.7 | 104.41 |
Operating Expenses | 710.82 | 839.98 | 906.33 | 1,737 | 2,932 | 3,437 |
Operating Income | -6.4 | 30.76 | -84.27 | -108.72 | 813.41 | 1,422 |
Interest Expense | -184 | -193.87 | -303.7 | -407.71 | -554.42 | -613.95 |
Interest & Investment Income | 175.28 | 184.11 | 599.53 | 83.97 | 251.17 | 329.82 |
Currency Exchange Gain (Loss) | -0.02 | -0.02 | 0 | -0 | 0.01 | -0.76 |
Other Non Operating Income (Expenses) | -40.15 | -47.31 | -77.37 | -169.88 | -121.5 | -142.3 |
EBT Excluding Unusual Items | -55.29 | -26.33 | 134.19 | -602.33 | 388.68 | 994.9 |
Impairment of Goodwill | - | - | -0.02 | -22.94 | -39.67 | -24.23 |
Gain (Loss) on Sale of Investments | 17.29 | 30.65 | -261.66 | -1,087 | 82.15 | -87.02 |
Gain (Loss) on Sale of Assets | 26.4 | 18.94 | -7.92 | -1 | 3.06 | 3.78 |
Asset Writedown | -1.32 | -0.61 | -4.89 | -24.89 | -0.24 | -1.2 |
Other Unusual Items | 19.77 | 18.93 | 4.89 | -4.98 | 31.04 | 30.06 |
Pretax Income | 6.84 | 41.57 | -135.42 | -1,744 | 465.02 | 916.3 |
Income Tax Expense | -16.77 | 0.55 | -167.39 | -4.88 | 83.01 | 290.93 |
Earnings From Continuing Operations | 23.62 | 41.02 | 31.97 | -1,739 | 382.01 | 625.37 |
Minority Interest in Earnings | -23.7 | -20.4 | -11.65 | -92.17 | -250.83 | -364.07 |
Net Income | -0.09 | 20.62 | 20.32 | -1,831 | 131.18 | 261.3 |
Net Income to Common | -0.09 | 20.62 | 20.32 | -1,831 | 131.18 | 261.3 |
Net Income Growth | - | 1.50% | - | - | -49.80% | - |
Shares Outstanding (Basic) | 1,499 | 1,505 | 1,505 | 1,477 | 1,458 | 1,452 |
Shares Outstanding (Diluted) | 1,499 | 1,505 | 1,505 | 1,477 | 1,458 | 1,452 |
Shares Change (YoY) | -0.64% | 0.01% | 1.93% | 1.30% | 0.40% | -2.99% |
EPS (Basic) | -0.00 | 0.01 | 0.01 | -1.24 | 0.09 | 0.18 |
EPS (Diluted) | -0.00 | 0.01 | 0.01 | -1.24 | 0.09 | 0.18 |
EPS Growth | - | 1.48% | - | - | -50.00% | - |
Free Cash Flow | 27.61 | 48.92 | -215.92 | 352.11 | -18.13 | -225.19 |
Free Cash Flow Per Share | 0.02 | 0.03 | -0.14 | 0.24 | -0.01 | -0.15 |
Dividend Per Share | 0.004 | 0.011 | 0.013 | - | 0.009 | 0.018 |
Dividend Growth | -80.00% | -15.38% | - | - | -50.00% | - |
Gross Margin | 9.63% | 10.93% | 10.23% | 13.23% | 17.78% | 17.84% |
Operating Margin | -0.09% | 0.39% | -1.05% | -0.88% | 3.86% | 5.22% |
Profit Margin | -0.00% | 0.26% | 0.25% | -14.87% | 0.62% | 0.96% |
Free Cash Flow Margin | 0.38% | 0.61% | -2.69% | 2.86% | -0.09% | -0.83% |
EBITDA | 114.99 | 192.34 | 130.9 | 165.95 | 1,113 | 1,713 |
EBITDA Margin | 1.57% | 2.41% | 1.63% | 1.35% | 5.29% | 6.29% |
D&A For EBITDA | 121.4 | 161.59 | 215.17 | 274.67 | 299.78 | 291.41 |
EBIT | -6.4 | 30.76 | -84.27 | -108.72 | 813.41 | 1,422 |
EBIT Margin | -0.09% | 0.39% | -1.05% | -0.88% | 3.86% | 5.22% |
Effective Tax Rate | - | 1.33% | - | - | 17.85% | 31.75% |
Revenue as Reported | 7,317 | 7,966 | 8,034 | 12,311 | 21,060 | 27,234 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.